How Multiplex-PCR Can Fit Into Diagnostic Testing Strategies for Pneumonia

Current diagnostic methods for lower respiratory specimens typically take one to two days to identify most bacterial pathogens. During that time, clinicians must rely on guideline recommendations and clinical diagnosis to guide empiric therapy, which is not optimized based on the patient’s individual pathogen. The BioFire Pneumonia Panel will provide pathogen identification in a much shorter timeframe and may allow clinicians to optimize targeted pathogen-specific therapy sooner. The BioFire Pneumonia Panel is a rapid multiplex-PCR test that identifies 33 targets, including 18 bacteria, 8 viruses and 7 antimicrobial resistance genes from lower respiratory tract specimens in about an hour. It provides semi-quantitative results (in copies/ml) for 15 of the bacterial targets. This new feature provided by multiplex-PCR testing may help clinicians and laboratorians separate colonizing from pathogenic levels of bacteria.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Covid Vaccines & Beyond - mRNA vaccine future uses and the role of excipient lipid nanoparticles

Registration fees are refundable for attendees registered for individual webinars, if cancellation is received at least five (5) business days prior to the course.
Watch Now

Building the Pharmaceutical Factory of the Future

Business-review-webinars

What is the Factory of the Future? It is a vision of a holistic company-wide transformation, which balances and combines: productivity, quality, and robustness based on a data-centric perspective. Is it possible to build the Pharma Factory of the Future today, increase quality and productivity, and decrease the cost at the same time?
Watch Now

Antioxidants, a safe and viable Inhibition Strategy for Nitrosamine Formation In Drug Products

Nitrosamines are potential mutagens and need to be controlled in human drug products. Recently, nitrosamine contamination of high-profile drugs has prompted numerous recalls, and increased regulatory assessments for marketed products.
Watch Now

How to get speed and depth in your Host Cell Protein (HCP) analysis

Technology Networks

In the rapidly expanding arena of biotherapeutic analysis and bioprocess development, the analysis of host cell proteins (HCP) is transitioning to a new phase. HCPs are contaminants in biotherapeutic drug preparations, often at low ppm concentration levels, and must be monitored due to stability, efficacy and immunogenicity concerns. Often, these protein impurities will be considered Critical Quality Attributes (CQA) and can contribute to an overall risk assessment for the product.
Watch Now